Uncategorized

Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen

Published

on

Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version